Aytu Biopharma Inc Stock Price, News & Analysis

Aytu BioPharma (Nasdaq: AYTU) announced that the U.S. method‑of‑use patent (U.S. Patent No. 7,538,116) for EXXUA (gepirone) extended‑release tablets was extended under 35 U.S.C. 156 through September 2, 2030. The extension supplements the NCE exclusivity previously granted by the FDA for gepirone, described as the first‑in‑class selective serotonin 5HT1a receptor agonist approved for treatment of major depressive disorder (MDD) in adults.

Management said EXXUA is on track for commercial launch in 2025 and that the company is discussing additional intellectual property and life‑cycle management options with its partner that may extend exclusivity beyond 2030. The release also cites an estimated 21 million Americans affected by MDD as the target patient population.

Aytu BioPharma (NASDAQ:AYTU) announced that management will participate in two investor conferences in October 2025.

Events: Maxim Growth Summit on October 22, 2025 in New York City, and Planet MicroCap Showcase: TORONTO 2025 on October 22–23, 2025 in Toronto. The Planet MicroCap presentation is scheduled for 2:30 p.m. ET and will be available via webcast.

Investor access: Investors may schedule one-on-one meetings by contacting their Maxim sales representative or Robert Blum of Lytham Partners at aytu@lythampartners.com. Registration is required to attend the Planet MicroCap Showcase and the webcast link is provided for remote viewing.

Aytu BioPharma (Nasdaq:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has announced its participation in two upcoming investor conferences in September 2025.

Management will present at the MicroCap Rodeo Fall Conference in New York City on September 25, 2025, at 2:00 PM ET, and at the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025, at 2:45 PM ET. Both presentations will be available via webcast, and management will conduct one-on-one meetings during both events.

Aytu BioPharma (NASDAQ:AYTU) reported its fiscal 2025 results with net revenue of $66.4 million, a 2% increase from fiscal 2024. The company posted a net loss of $13.6 million and adjusted EBITDA of $9.2 million, with a strong cash position of $31.0 million as of June 30, 2025.

The company's ADHD Portfolio generated $57.6 million in revenue, while the Pediatric Portfolio contributed $8.8 million. A significant highlight is Aytu's exclusive agreement to commercialize EXXUA, a novel first-in-class treatment for major depressive disorder (MDD), with launch planned for Q4 2025 targeting the $22 billion U.S. MDD market.

Aytu BioPharma (NASDAQ:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has scheduled its fiscal 2025 full year and fourth quarter financial results announcement for September 23, 2025, after market close.

The company will host a conference call and webcast at 4:30 p.m. Eastern time on the same day, featuring a results review and Q&A session. The call will be accessible via phone and webcast, with replay available until October 7, 2025.

Aytu BioPharma (Nasdaq:AYTU) has appointed Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs, effective June 30, 2025. Dr. Westfield, a former Aytu executive and Nobel Prize contributor, will oversee medical and scientific affairs strategies, focusing on the commercial launch of EXXUA™.

EXXUA, a novel FDA-approved treatment for major depressive disorder (MDD), is set to launch in Q4 2025. As the first-in-class selective serotonin 5HT1a receptor agonist, EXXUA will compete in the $22 billion U.S. prescription MDD market. Notably, it's the only serotonin-targeting antidepressant without sexual dysfunction warnings, and has been tested in over 5,000 patients.

Aytu BioPharma has expanded and extended its lending agreement with Eclipse Business Capital, strengthening its financial position ahead of EXXUA's commercial launch. The term loan maturity has been extended to June 2029, with the principal balance increased to $13.0 million from $11.1 million. The revolving credit facility has been expanded by $1.5 million. This follows Aytu's recent exclusive agreement to commercialize EXXUA, a first-in-class antidepressant for major depressive disorder, in the U.S. market worth over $22 billion. EXXUA has shown promising results in clinical trials with over 5,000 patients, demonstrating significant improvement in depression symptoms with sexual side effects comparable to placebo. The company recently closed a $16.6 million public offering and plans to launch EXXUA in Q4 2025.

Aytu BioPharma has closed an upsized at-the-market public offering, raising $16.6 million in gross proceeds through the sale of common stock and prefunded warrants. The offering was led by healthcare-focused institutional investors including Nantahala Capital Management and Stonepine Capital Management. The funds will support the commercialization of EXXUA, a first-in-class FDA-approved antidepressant for Major Depressive Disorder (MDD). EXXUA, a selective serotonin 5HT1a receptor agonist, has shown significant improvement in depression symptoms across 5,000+ patient trials with sexual side effects comparable to placebo. Unlike SSRIs, EXXUA has no reuptake inhibition activity and shows no significant adverse effects on weight, blood pressure, heart rate, or liver function. The company plans to launch EXXUA in Q4 2025, targeting the $22 billion US prescription MDD market.

Aytu BioPharma (NASDAQ:AYTU) has announced the pricing of an upsized public offering of 9.6 million shares of common stock at $1.50 per share, with potential for an additional 1.44 million shares through a 30-day underwriter option. The offering, led by Nantahala Capital Management and Stonepine Capital Management, is expected to raise approximately $14.4 million in gross proceeds. The company plans to use the funds for general corporate purposes, working capital, and to secure exclusive commercialization rights for EXXUA, an FDA-approved treatment for major depressive disorder. Lake Street Capital Markets is acting as sole book runner, with Maxim Group as lead manager. The offering is expected to close around June 9, 2025.